Amid backlash, FDA changes course over shortage of Lilly weight-loss drugs
The U.S. Food and Drug Administration, after intense public pressure and a lawsuit, is reconsidering its declaration barely two weeks ago that a shortage of the appetite-suppressing drugs Mounjaro and Zepbound—both made by Indianapolis-based Eli Lilly and Co.—is over, a temporary about-face that will allow pharmacies to keep selling unbranded copies.